CELLULAR IMMUNITY INDICATORS IN NEWBORNS WITH HEMOLYTIC DISEASE UNDERGOING HIGH-TECH FETAL SURGERY

One of the most serious complications of pregnancy in women is fetal and neonatal hemolytic disease, which develops as a result of the breakdown of red blood cells in the fetus under the influence of maternal anti-Rhesus antibodies. The aim of the study: Was to evaluate cellular immunity factors such as CD3+ basic T-lymphocytes, CD4+ T-helper cells, CD8+ T-suppressors, CD16+ T-killers, CD20+ B-lymphocytes and immunoregulatory index, in the cord blood of newborns with hemolytic disease caused by Rhesus conflict in pregnant women and who were treated in the antenatal period by intrauterine, intravascular hemotransfusion to the fetus. Materials and methods: The studies were conducted at Republican perinatal center for the year 2024. A total of 50 newborns participated in the study and were divided into 3 groups. The 1st main group of 20 newborns with hemolytic disease who underwent "intrauterine, intravascular fetal hemotransfusion" surgery in the prenatal period, the 2nd comparison group of 20 newborns with hemolytic disease who did not undergo fetal surgery in the prenatal period, and the 3rd control group of 10 healthy newborns. All immunological studies were conducted at the Institute of Immunology of the Academy of Sciences of the Republic of Uzbekistan. Conclusions. Intrauterine intravascular hemotransfusion to the fetus not only improves hematological parameters of fetal blood, but also improves the indicators of cellular immunity, in particular, contributes to the increase in the number of T lymphocytes, which favorably affects T-cell immunity and prevents the formation of immunodeficiency state at birth.